SI2311434T1 - Formulacije za inhalator suhega praška, ki vsebujejo površinsko modificirane delce z aditivi proti sprijemanju - Google Patents

Formulacije za inhalator suhega praška, ki vsebujejo površinsko modificirane delce z aditivi proti sprijemanju

Info

Publication number
SI2311434T1
SI2311434T1 SI200532009T SI200532009T SI2311434T1 SI 2311434 T1 SI2311434 T1 SI 2311434T1 SI 200532009 T SI200532009 T SI 200532009T SI 200532009 T SI200532009 T SI 200532009T SI 2311434 T1 SI2311434 T1 SI 2311434T1
Authority
SI
Slovenia
Prior art keywords
dry powder
powder inhaler
modified particles
particles
inhaler formulations
Prior art date
Application number
SI200532009T
Other languages
English (en)
Slovenian (sl)
Inventor
David Morton
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33548732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2311434(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Limited filed Critical Vectura Limited
Publication of SI2311434T1 publication Critical patent/SI2311434T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
SI200532009T 2004-11-23 2005-11-23 Formulacije za inhalator suhega praška, ki vsebujejo površinsko modificirane delce z aditivi proti sprijemanju SI2311434T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425758.0A GB0425758D0 (en) 2004-11-23 2004-11-23 Preparation of pharmaceutical compositions
EP10179073.1A EP2311434B1 (en) 2004-11-23 2005-11-23 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives

Publications (1)

Publication Number Publication Date
SI2311434T1 true SI2311434T1 (sl) 2015-11-30

Family

ID=33548732

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200531874T SI2174653T1 (sl) 2004-11-23 2005-11-23 Formulacije suhega praška za inhalacijo, ki obsegajo površinsko modificirane delce z dodatki proti zlepljenju
SI200532009T SI2311434T1 (sl) 2004-11-23 2005-11-23 Formulacije za inhalator suhega praška, ki vsebujejo površinsko modificirane delce z aditivi proti sprijemanju

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200531874T SI2174653T1 (sl) 2004-11-23 2005-11-23 Formulacije suhega praška za inhalacijo, ki obsegajo površinsko modificirane delce z dodatki proti zlepljenju

Country Status (15)

Country Link
US (4) US20080127972A1 (enExample)
EP (4) EP2174653B1 (enExample)
JP (2) JP5339401B2 (enExample)
CN (2) CN104146960A (enExample)
AT (1) ATE456363T1 (enExample)
DE (1) DE602005019192D1 (enExample)
DK (2) DK2174653T3 (enExample)
ES (3) ES2490240T3 (enExample)
GB (1) GB0425758D0 (enExample)
HU (1) HUE027465T2 (enExample)
IN (1) IN2014CN04336A (enExample)
PL (3) PL1814521T3 (enExample)
PT (3) PT2174653E (enExample)
SI (2) SI2174653T1 (enExample)
WO (1) WO2006056812A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
AU2009272445B2 (en) 2008-07-18 2012-11-22 Circassia Limited Process for improving crystallinity
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
KR101730684B1 (ko) * 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말을 위한 담체 입자 제조 방법
EP2560611B1 (en) * 2010-04-21 2018-01-03 Chiesi Farmaceutici S.p.A. "process for providing particles with reduced electrostatic charges"
CN102309456B (zh) * 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
CN103200938B (zh) * 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812414C (en) * 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
US20150136130A1 (en) * 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
HUE029420T2 (en) 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103588846B (zh) * 2012-08-15 2016-08-03 重庆华邦制药有限公司 一种丙酸氟替卡松微粒的制备方法及其用途
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
NZ715797A (en) 2013-07-11 2020-06-26 Chiesi Farm Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
MX381173B (es) 2013-10-08 2025-03-12 Ai Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
PL3107548T3 (pl) * 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji
MX394266B (es) 2014-04-04 2025-03-24 Ai Therapeutics Inc Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
EA201692456A1 (ru) 2014-07-09 2017-08-31 Арвен Иладж Санайи Ве Тиджарет А.Ш. Способ получения составов для ингаляции
CN116687887A (zh) 2014-07-31 2023-09-05 维克图拉公司 用于吸入的干粉制剂
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20160119692A1 (en) * 2014-10-24 2016-04-28 Sunshine Partners LLC Interactive system and method for viewer selection of objects in context while viewing television
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10853435B2 (en) 2016-06-17 2020-12-01 Axon Enterprise, Inc. Systems and methods for aligning event data
AU2017286864A1 (en) * 2016-06-30 2018-11-15 Philip Morris Products S.A. Nicotine particles and compositions
WO2018002779A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles
WO2018071757A1 (en) * 2016-10-14 2018-04-19 Pulmatrix Operating Company, Inc. Antifungal dry powders
WO2018163085A1 (en) * 2017-03-07 2018-09-13 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US11590298B2 (en) 2017-06-02 2023-02-28 Csp Technologies, Inc. Inhaler and methods of using and making same
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Aspeya US Inc. Dry powder compositions with magnesium stearate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
WO2023128913A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
KR20250084912A (ko) 2022-07-04 2025-06-11 호비온 사이언티아 리미티드 흡입을 위한 코팅된 결정형 건조 분말의 건조 분말 흡입기 약학 조성물
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
GB2633305B (en) 2023-08-30 2025-11-26 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery
CN120678762A (zh) * 2024-03-20 2025-09-23 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
CN119055610A (zh) * 2024-08-27 2024-12-03 江苏谦仁生物科技有限公司 一种阿昔莫司胶囊及其制备方法
CN119371006B (zh) * 2024-11-06 2025-07-04 北京城市排水集团有限责任公司 一种长效缓释型污泥脱氮菌群调节药剂及制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
ES2087911T3 (es) 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
EP0931595A1 (en) 1998-01-26 1999-07-28 Imra Europe S.A. A device for spraying a liquid
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
CA2371836C (en) 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
JP2001072586A (ja) 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
PT1219609E (pt) 1999-09-16 2007-06-19 Tanabe Seiyaku Co ''compostos cíclicos aromático azotados de seis membros''
FI20002217L (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
IL151614A0 (en) 2000-04-07 2003-04-10 Tap Holdings Inc Apomorphine derivatives and methods for their use
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP1276474B1 (en) 2000-04-17 2007-06-13 Vectura Limited Formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
EP2266549B1 (en) * 2000-06-27 2019-08-07 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
WO2002009669A2 (en) 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
KR20030077538A (ko) 2000-11-15 2003-10-01 탭 파마슈티칼 프로덕츠 인코포레이티드 항우울제-유도된 성기능 장애를 아포모르핀을 사용하여치료하는 방법
US20020086876A1 (en) 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
AU2002215114A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
US8580306B2 (en) * 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
EP1337240B2 (en) * 2000-11-30 2014-09-24 Vectura Limited Method of making particles for use in a pharmaceutical composition
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
ATE502623T1 (de) 2000-12-27 2011-04-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen
GB0109384D0 (en) * 2001-04-12 2001-05-30 Vectura Ltd Pharmaceutical products, preparation and uses thereof
EP1392383A2 (en) 2001-05-10 2004-03-03 Vectura Delivery Devices Limited Inhalers
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
EP1423092A2 (en) * 2001-09-05 2004-06-02 Vectura Limited Functional powders for oral delivery
US20030175355A1 (en) * 2002-03-07 2003-09-18 Tobyn Michael John Fast melt multiparticulate formulations for oral delivery
US20040003341A1 (en) 2002-06-20 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for processing electronic forms for use with resource constrained devices
AU2003269284A1 (en) * 2002-10-11 2004-05-04 Pharmakodex Limited Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof
CA2522158C (en) * 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
AU2004228757A1 (en) 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
EP1663164A2 (en) * 2003-09-15 2006-06-07 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
DK2311434T3 (en) 2015-10-05
CA2589514C (en) 2014-07-22
JP5339401B2 (ja) 2013-11-13
EP2311434A1 (en) 2011-04-20
EP2949317A1 (en) 2015-12-02
CN101106975A (zh) 2008-01-16
WO2006056812A1 (en) 2006-06-01
PL2174653T3 (pl) 2014-11-28
CN104146960A (zh) 2014-11-19
JP5579669B2 (ja) 2014-08-27
PL2311434T3 (pl) 2015-12-31
EP2311434B1 (en) 2015-07-08
US20170216203A1 (en) 2017-08-03
IN2014CN04336A (enExample) 2015-09-04
EP2174653B1 (en) 2014-05-14
US9585834B2 (en) 2017-03-07
ATE456363T1 (de) 2010-02-15
GB0425758D0 (en) 2004-12-22
US20080127972A1 (en) 2008-06-05
PT2311434E (pt) 2015-10-23
DK2174653T3 (da) 2014-08-11
PT1814521E (pt) 2010-04-16
US20110236492A1 (en) 2011-09-29
EP1814521B1 (en) 2010-01-27
EP1814521A1 (en) 2007-08-08
US9642800B2 (en) 2017-05-09
CA2589514A1 (en) 2006-06-01
SI2174653T1 (sl) 2014-10-30
PL1814521T3 (pl) 2010-07-30
ES2340599T3 (es) 2010-06-07
EP2949317B1 (en) 2017-01-04
ES2548884T3 (es) 2015-10-21
DE602005019192D1 (de) 2010-03-18
US20160000709A1 (en) 2016-01-07
PT2174653E (pt) 2014-08-25
JP2011201925A (ja) 2011-10-13
JP2008520307A (ja) 2008-06-19
HUE027465T2 (en) 2016-09-28
ES2490240T3 (es) 2014-09-03
EP2174653A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
PL2311434T3 (pl) Preparaty do inhalatora suchego proszku zawierające cząsteczki o zmodyfikowanej powierzchni z dodatkami zapobiegającymi adhezji
SG161203A1 (en) Nanoparticulate tacrolimus formulations
WO2008084312A3 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1915163A4 (en) COMPOSITIONS OF POLYETHYL AND POLYETHERS AND METHOD FOR THEIR USE AS SKIN FILLERS
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
NO20025873L (no) Meget effektiv levering av en stor terapeutisk mengde aerosol
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
TW200613479A (en) Coating formulation having improved rheological properties
IL218317A (en) Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs
WO2008008733A3 (en) Nanoparticulate sorafenib formulations
MY155299A (en) Oral dosage composition
MY150531A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
BR0110139A (pt) Formulações farmacêuticas para inaladores de pó seco
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
PT1337239E (pt) Partículas servindo à preparação de uma composição farmacêutica
ATE453382T1 (de) Pulver zur nasalen verabreichung von wirkstoffen
MX368774B (es) Nueva dosificación y formulación.
WO2006008517A3 (en) Use of dry powder compositions for pulmonary delivery
MX2009008487A (es) Picoplatino encapsulado.
WO2005041922A3 (en) Composition
WO2008066810A3 (en) Pleasant tasting dry powder compositions suitable for pulmonary delivery
WO2002043693A3 (en) Pharmaceutical compositions for inhalation
PL2051693T3 (pl) Kompozycja farmaceutyczna, łatwa do połknięcia i nie powodująca nieprzyjemnych odczuć w ustach, zawierająca cząstki z substancją czynną
TW200730170A (en) Micronised azodicarbonamide, and the preparation and use thereof